[Immune evasion mechanism and its clinical application value in Hodgkin's lymphoma].

Tao, Y X; Shi, Y K

Tao, Y X; Shi, Y K.

Afiliación

Tao YX; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Shi YK; Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Zhonghua Zhong Liu Za Zhi ; 43(9): 917-923, 2021 Sep 23.

Article en Zh | MEDLINE | ID: mdl-34530573

Asunto(s)

Enfermedad de Hodgkin; Apoptosis; Enfermedad de Hodgkin/tratamiento farmacológico; Humanos; Evasión Inmune; Células de Reed-Sternberg; Transducción de Señal; Microambiente Tumoral

Palabras clave

Hodgkin's lymphoma; Immune evasion; New drug; Prognostic marker; Tumor microenvironment

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Hodgkin Límite: Humans Idioma: Zh Revista: Zhonghua Zhong Liu Za Zhi Año: 2021 Tipo del documento: Article País de afiliación: China

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google